Upstream Bio Statistics
Total Valuation
Upstream Bio has a market cap or net worth of $157.19 million. The enterprise value is -$103.16 million.
| Market Cap | 157.19M |
| Enterprise Value | -103.16M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Upstream Bio has 54.77 million shares outstanding. The number of shares has increased by 38.95% in one year.
| Current Share Class | 54.77M |
| Shares Outstanding | 54.77M |
| Shares Change (YoY) | +38.95% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 75.91% |
| Float | 42.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 50.99 |
| Forward PS | 107.17 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.99, with a Debt / Equity ratio of 0.00.
| Current Ratio | 27.99 |
| Quick Ratio | 26.38 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -46.05% and return on invested capital (ROIC) is -31.15%.
| Return on Equity (ROE) | -46.05% |
| Return on Assets (ROA) | -30.28% |
| Return on Invested Capital (ROIC) | -31.15% |
| Return on Capital Employed (ROCE) | -62.68% |
| Weighted Average Cost of Capital (WACC) | 11.83% |
| Revenue Per Employee | $42,107 |
| Profits Per Employee | -$2.09M |
| Employee Count | 75 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.55% in the last 52 weeks. The beta is 1.39, so Upstream Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.39 |
| 52-Week Price Change | -86.55% |
| 50-Day Moving Average | 5.25 |
| 200-Day Moving Average | 9.85 |
| Relative Strength Index (RSI) | 26.25 |
| Average Volume (20 Days) | 1,226,042 |
Short Selling Information
The latest short interest is 4.51 million, so 8.24% of the outstanding shares have been sold short.
| Short Interest | 4.51M |
| Short Previous Month | 4.49M |
| Short % of Shares Out | 8.24% |
| Short % of Float | 10.55% |
| Short Ratio (days to cover) | 7.05 |
Income Statement
In the last 12 months, Upstream Bio had revenue of $3.16 million and -$156.50 million in losses. Loss per share was -$2.89.
| Revenue | 3.16M |
| Gross Profit | 3.16M |
| Operating Income | -169.98M |
| Pretax Income | -156.50M |
| Net Income | -156.50M |
| EBITDA | -169.78M |
| EBIT | -169.98M |
| Loss Per Share | -$2.89 |
Balance Sheet
The company has $261.31 million in cash and $954,000 in debt, with a net cash position of $260.35 million or $4.75 per share.
| Cash & Cash Equivalents | 261.31M |
| Total Debt | 954,000 |
| Net Cash | 260.35M |
| Net Cash Per Share | $4.75 |
| Equity (Book Value) | 270.96M |
| Book Value Per Share | 4.95 |
| Working Capital | 269.61M |
Cash Flow
In the last 12 months, operating cash flow was -$136.34 million and capital expenditures -$118,000, giving a free cash flow of -$136.46 million.
| Operating Cash Flow | -136.34M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | 202,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -136.46M |
| FCF Per Share | -$2.49 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -5,382.65% |
| Pretax Margin | -4,955.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Upstream Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.95% |
| Shareholder Yield | -38.95% |
| Earnings Yield | -100.55% |
| FCF Yield | -84.74% |
Analyst Forecast
The average price target for Upstream Bio is $29.83, which is 939.37% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.83 |
| Price Target Difference | 939.37% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -25.80% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Upstream Bio has an Altman Z-Score of 50.27 and a Piotroski F-Score of 2.
| Altman Z-Score | 50.27 |
| Piotroski F-Score | 2 |